Skip to main content

Raise Your Profile

Whether you are looking to attract a new business client, investment and partnering deal flow or talent, among other goals, One Nucleus offers a wide range of opportunities to raise your profile to our members and others in the Cambridge-London life sciences corridor, and wider local and international ecosystems.
Raise Your Profile
  • Discounts for Members

    Discounts for Members

    Members can take advantage of discounts on a wide range of products and services to maximise their return on the member subscription, often recovering multiples of the fees paid. Receive discounted rates on laboratory supplies, services, key industry events and more.
    Learn more
  • Connect with Our Network

    Connect with Our Network

    A key advantage to any company joining One Nucleus is the ability to connect to potential partners, investors, service providers, clients and their peers for knowledge-sharing. We do this through our varied range of informative networking events, which tend to be situated throughout Cambridge and London.
    Learn more
  • Build the Best Teams

    Build the Best Teams

    One Nucleus recognises that a company’s employees are its most valuable asset and the competition for talented and skilled employees has never been fiercer in the region’s life science sector. One Nucleus offers a range of services and engagement opportunities in this critical area to help support our members and maintain the reputation of the sector.
    Learn more

Events

Connecting and meeting with business partners, fellow innovators and key advisers is a vital part of everyone's endeavours since it enables knowledge exchange and onward contact for mutual and collective success. Complementing the wider One Nucleus support activities our portfolio of events is designed to meet the needs of our network in terms of content, format, timing, peer-to-peer engagements and modes of delivery.
  • Events
  • Events
  • Events
  • Events

Membership Overview

With Gold and Silver membership options, our 400 company members and their staff can benefit from a wide variety of savings, profiling opportunities, and more.
  • Membership

About One Nucleus

One Nucleus is a not-for-profit Life Sciences & Healthcare membership organisation headquartered in Cambridge. We support institutions, companies and individuals in the Life Sciences sector providing local, UK-wide and international connectivity. 
  • About

NRG Therapeutics Announces a PET Biodistribution Trial of Lead Clinical Asset NRG5051

Stevenage, UK, 21 October 2026 - NRG Therapeutics Ltd. (“NRG”), an innovative clinical stage neuroscience company targeting a novel mechanism to restore mitochondrial dysfunction in neurodegenerative diseases, today announced a positron emission tomography (PET) imaging trial (NRG5051-102) to assess the biodistribution of its lead clinical asset NRG5051 has started.

NRG5051 is an orally bioavailable and CNS-penetrant next-generation inhibitor of the mitochondrial permeability transition pore (mPTP) that acts through a novel NLRX1-mediated mechanism of action.

Two Climate-Tech Startups Join Growing Cluster at Discovery Park

Sandwich, UK — 13 October 2026: Discovery Park, Kent’s business park for science and technology companies, today welcomed two climate-tech companies to its innovation campus. Anthera Remediation Technologies, tackling 'forever chemicals' in water and soil, and Colliding Materials, building plastic compounding technology for sustainable energy systems, have now moved into new laboratory spaces in Sandwich, Kent.

CN Bio e-Symposium 2026: From Insight to Decision

Join scientists from leading pharmaceutical, biotechnology and academic organizations as they share how they are applying Organ-on-a-Chip (OOC) human-relevant models to improve decision-making across research and development.

The program includes a dedicated OOC Masterclass, designed to help attendees understand the technology, explore practical applications and learn how others are successfully implementing these approaches.

Bionow BioInfect 2027 Conference

Turning Insight into Impact

BioInfect brings together experts from across research, biotech, pharma, healthcare, clinical practice and policy to explore one of the most significant challenges facing global health: antimicrobial resistance (AMR). Through expert insight, industry perspectives and valuable networking opportunities, the conference provides a forum for collaboration, knowledge sharing and action.

Amphista Therapeutics Announces First Patient Dosed in AMX-883 Phase 1 Clinical Trial for Acute Myeloid Leukemia

  • AMX-883, Amphista’s first asset to enter the clinic, is a potent, selective, orally bioavailable DCAF16-mediated BRD9 degrader targeting acute myeloid leukemia (AML)
  • The first-in-human ‘BRAMLIE’ (BR(D9) AML Interventional Evaluation) trial will assess the safety, pharmacokinetics and preliminary efficacy of AMX-883 monotherapy in participants with AML and high-risk myelodysplastic syndrome (MDS)
Subscribe to